Preprint Brief Report Version 1 Preserved in Portico This version is not peer-reviewed

Comparison of Antibody Persistence Up to 6 Months After Additional Booster Vaccination With ChAdOx1 nCoV-19 Vaccine.

Pawita Suwanwattana
,
May Han
,
Tanawin Nopsopon
* ORCID logo ,
Phanupong Phutrakool
,
Chatpol Samuthpongtorn
,
Wannarat Pongpirul
,
Wisit Prasithsirikul
ORCID logo ,
Anan Jongkaewwattana
ORCID logo ,
Krit Pongpirul
*
Version 1 : Received: 13 April 2023 / Approved: 14 April 2023 / Online: 14 April 2023 (10:20:45 CEST)

A peer-reviewed article of this Preprint also exists.

Suwanwattana, P.; Han, M.; Nopsopon, T.; Phutrakool, P.; Samuthpongtorn, C.; Pongpirul, W.; Prasithsirikul, W.; Pongpirul, K. Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 NCoV-19 Vaccine. Microbiology Research 2023, 14, 810–818, doi:10.3390/microbiolres14020057. Suwanwattana, P.; Han, M.; Nopsopon, T.; Phutrakool, P.; Samuthpongtorn, C.; Pongpirul, W.; Prasithsirikul, W.; Pongpirul, K. Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 NCoV-19 Vaccine. Microbiology Research 2023, 14, 810–818, doi:10.3390/microbiolres14020057.

Abstract

Vaccines are crucial for controlling the COVID-19 pandemic, and booster doses are becoming increasingly important. This study aimed to assess the efficacy of the ChAdOx1 nCoV-19 vaccine from AstraZeneca as a third dose in healthcare workers at different time intervals (one, three, and six months). Two methods to measure immune response—ELISA (EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany) and ELISpot (Mabtech AB, Macka Strand, Sweden)—were used. A total of 170 participants were included in the study. The results showed that while IgG levels decreased at six months compared to levels at one and three months, they were still significantly higher than the baseline. Furthermore, neutralizing levels at three and six months after the third dose were not significantly different. These findings suggest that the immune response induced by the vaccine is robust and effective for several months. These results have significant implications for public health policymakers, as they provide strong support for booster vaccinations. The ChAdOx1 nCoV-19 vaccine appears to be a reliable option for preventing the spread of COVID-19, and this study provides valuable information for healthcare workers and policymakers in managing the pandemic.

Keywords

ChAdOx1 nCoV-19; immunogenicity; SARS-CoV-2; COVID-19; neutralizing antibodies; durability; booster

Subject

Medicine and Pharmacology, Epidemiology and Infectious Diseases

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.